nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Sorafenib—liver cancer	0.275	0.515	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—liver cancer	0.167	0.312	CbGbCtD
Eprosartan—ABCC2—bile canaliculus—liver cancer	0.119	0.62	CbGeAlD
Eprosartan—CYP2C9—Sorafenib—liver cancer	0.0925	0.173	CbGbCtD
Eprosartan—ABCC2—bile duct—liver cancer	0.0372	0.194	CbGeAlD
Eprosartan—ABCC2—bile—liver cancer	0.0286	0.149	CbGeAlD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00365	0.0486	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00358	0.0478	CbGpPWpGaD
Eprosartan—AGTR1—liver—liver cancer	0.00322	0.0168	CbGeAlD
Eprosartan—ABCC2—liver—liver cancer	0.00233	0.0121	CbGeAlD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00216	0.0288	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00209	0.0279	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00206	0.0275	CbGpPWpGaD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00193	0.0257	CbGpPWpGaD
Eprosartan—Serum creatinine increased—Epirubicin—liver cancer	0.0016	0.00805	CcSEcCtD
Eprosartan—CYP2C9—liver—liver cancer	0.00155	0.00807	CbGeAlD
Eprosartan—AGTR1—Allograft Rejection—IL12A—liver cancer	0.00154	0.0205	CbGpPWpGaD
Eprosartan—Serum creatinine increased—Doxorubicin—liver cancer	0.00148	0.00745	CcSEcCtD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—liver cancer	0.00146	0.0195	CbGpPWpGaD
Eprosartan—Renal failure—Sorafenib—liver cancer	0.00146	0.00737	CcSEcCtD
Eprosartan—Neuropathy peripheral—Sorafenib—liver cancer	0.00146	0.00735	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CCR4—liver cancer	0.00144	0.0192	CbGpPWpGaD
Eprosartan—Epistaxis—Sorafenib—liver cancer	0.0014	0.00707	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—HGF—liver cancer	0.00135	0.018	CbGpPWpGaD
Eprosartan—Albuminuria—Epirubicin—liver cancer	0.00131	0.00664	CcSEcCtD
Eprosartan—Neuritis—Epirubicin—liver cancer	0.00131	0.00664	CcSEcCtD
Eprosartan—ABCC2—Irinotecan Pathway—APC—liver cancer	0.00131	0.0174	CbGpPWpGaD
Eprosartan—Otitis media—Epirubicin—liver cancer	0.00126	0.00636	CcSEcCtD
Eprosartan—Gingivitis—Epirubicin—liver cancer	0.00125	0.00631	CcSEcCtD
Eprosartan—Tinnitus—Sorafenib—liver cancer	0.00124	0.00628	CcSEcCtD
Eprosartan—CYP2C9—CYP2E1 reactions—CYP2E1—liver cancer	0.00124	0.0165	CbGpPWpGaD
Eprosartan—Neuritis—Doxorubicin—liver cancer	0.00122	0.00614	CcSEcCtD
Eprosartan—Albuminuria—Doxorubicin—liver cancer	0.00122	0.00614	CcSEcCtD
Eprosartan—Glycosuria—Epirubicin—liver cancer	0.00121	0.00611	CcSEcCtD
Eprosartan—Rigors—Epirubicin—liver cancer	0.0012	0.00607	CcSEcCtD
Eprosartan—Otitis media—Doxorubicin—liver cancer	0.00117	0.00589	CcSEcCtD
Eprosartan—Gingivitis—Doxorubicin—liver cancer	0.00116	0.00584	CcSEcCtD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—liver cancer	0.00115	0.0153	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00114	0.0152	CbGpPWpGaD
Eprosartan—Glycosuria—Doxorubicin—liver cancer	0.00112	0.00566	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—DNAJB1—liver cancer	0.00112	0.0149	CbGpPWpGaD
Eprosartan—Muscle spasms—Sorafenib—liver cancer	0.00112	0.00563	CcSEcCtD
Eprosartan—Rigors—Doxorubicin—liver cancer	0.00111	0.00561	CcSEcCtD
Eprosartan—Viral infection—Epirubicin—liver cancer	0.00109	0.00548	CcSEcCtD
Eprosartan—Arthropathy—Epirubicin—liver cancer	0.00108	0.00545	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—MET—liver cancer	0.00107	0.0142	CbGpPWpGaD
Eprosartan—Herpes simplex—Epirubicin—liver cancer	0.00106	0.00538	CcSEcCtD
Eprosartan—Angioedema—Sorafenib—liver cancer	0.00106	0.00535	CcSEcCtD
Eprosartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.00104	0.0139	CbGpPWpGaD
Eprosartan—Syncope—Sorafenib—liver cancer	0.00104	0.00526	CcSEcCtD
Eprosartan—Bone pain—Epirubicin—liver cancer	0.00102	0.00517	CcSEcCtD
Eprosartan—Loss of consciousness—Sorafenib—liver cancer	0.00102	0.00515	CcSEcCtD
Eprosartan—Cough—Sorafenib—liver cancer	0.00101	0.00511	CcSEcCtD
Eprosartan—Viral infection—Doxorubicin—liver cancer	0.00101	0.00507	CcSEcCtD
Eprosartan—Arthropathy—Doxorubicin—liver cancer	0.000998	0.00504	CcSEcCtD
Eprosartan—Myalgia—Sorafenib—liver cancer	0.000988	0.00499	CcSEcCtD
Eprosartan—Arthralgia—Sorafenib—liver cancer	0.000988	0.00499	CcSEcCtD
Eprosartan—Herpes simplex—Doxorubicin—liver cancer	0.000985	0.00497	CcSEcCtD
Eprosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—liver cancer	0.000983	0.0131	CbGpPWpGaD
Eprosartan—Dry mouth—Sorafenib—liver cancer	0.000966	0.00488	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL12B—liver cancer	0.000965	0.0129	CbGpPWpGaD
Eprosartan—Cystitis noninfective—Epirubicin—liver cancer	0.000958	0.00484	CcSEcCtD
Eprosartan—Influenza like illness—Epirubicin—liver cancer	0.000953	0.00481	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.000949	0.0127	CbGpPWpGaD
Eprosartan—Bone pain—Doxorubicin—liver cancer	0.000948	0.00479	CcSEcCtD
Eprosartan—Cystitis—Epirubicin—liver cancer	0.000947	0.00478	CcSEcCtD
Eprosartan—Shock—Sorafenib—liver cancer	0.000932	0.00471	CcSEcCtD
Eprosartan—Thrombocytopenia—Sorafenib—liver cancer	0.000927	0.00468	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00092	0.0123	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000904	0.0121	CbGpPWpGaD
Eprosartan—Anorexia—Sorafenib—liver cancer	0.000903	0.00456	CcSEcCtD
Eprosartan—Cramps of lower extremities—Epirubicin—liver cancer	0.000901	0.00455	CcSEcCtD
Eprosartan—Oesophagitis—Epirubicin—liver cancer	0.000897	0.00453	CcSEcCtD
Eprosartan—Rash maculo-papular—Epirubicin—liver cancer	0.000892	0.0045	CcSEcCtD
Eprosartan—Bladder pain—Epirubicin—liver cancer	0.000887	0.00448	CcSEcCtD
Eprosartan—Cystitis noninfective—Doxorubicin—liver cancer	0.000887	0.00448	CcSEcCtD
Eprosartan—Influenza like illness—Doxorubicin—liver cancer	0.000882	0.00445	CcSEcCtD
Eprosartan—Cystitis—Doxorubicin—liver cancer	0.000877	0.00443	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000863	0.00436	CcSEcCtD
Eprosartan—Abnormal vision—Epirubicin—liver cancer	0.000856	0.00432	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.000846	0.0113	CbGpPWpGaD
Eprosartan—Dyspnoea—Sorafenib—liver cancer	0.000844	0.00426	CcSEcCtD
Eprosartan—Cramps of lower extremities—Doxorubicin—liver cancer	0.000834	0.00421	CcSEcCtD
Eprosartan—Dyspepsia—Sorafenib—liver cancer	0.000834	0.00421	CcSEcCtD
Eprosartan—Oesophagitis—Doxorubicin—liver cancer	0.00083	0.00419	CcSEcCtD
Eprosartan—Rash maculo-papular—Doxorubicin—liver cancer	0.000825	0.00417	CcSEcCtD
Eprosartan—Decreased appetite—Sorafenib—liver cancer	0.000823	0.00416	CcSEcCtD
Eprosartan—Bladder pain—Doxorubicin—liver cancer	0.000821	0.00414	CcSEcCtD
Eprosartan—Diabetes mellitus—Epirubicin—liver cancer	0.000819	0.00413	CcSEcCtD
Eprosartan—Fatigue—Sorafenib—liver cancer	0.000817	0.00412	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK14—liver cancer	0.000815	0.0109	CbGpPWpGaD
Eprosartan—Constipation—Sorafenib—liver cancer	0.00081	0.00409	CcSEcCtD
Eprosartan—Pain—Sorafenib—liver cancer	0.00081	0.00409	CcSEcCtD
Eprosartan—Vascular purpura—Epirubicin—liver cancer	0.000796	0.00402	CcSEcCtD
Eprosartan—Eczema—Epirubicin—liver cancer	0.000793	0.004	CcSEcCtD
Eprosartan—Abnormal vision—Doxorubicin—liver cancer	0.000792	0.004	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—F2—liver cancer	0.000789	0.0105	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Sorafenib—liver cancer	0.000775	0.00391	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP2E1—liver cancer	0.000766	0.0102	CbGpPWpGaD
Eprosartan—Hot flush—Epirubicin—liver cancer	0.000761	0.00384	CcSEcCtD
Eprosartan—Diabetes mellitus—Doxorubicin—liver cancer	0.000758	0.00383	CcSEcCtD
Eprosartan—Menopausal symptoms—Epirubicin—liver cancer	0.000755	0.00381	CcSEcCtD
Eprosartan—Urticaria—Sorafenib—liver cancer	0.000752	0.0038	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.00075	0.01	CbGpPWpGaD
Eprosartan—Body temperature increased—Sorafenib—liver cancer	0.000749	0.00378	CcSEcCtD
Eprosartan—Abdominal pain—Sorafenib—liver cancer	0.000749	0.00378	CcSEcCtD
Eprosartan—Purpura—Epirubicin—liver cancer	0.000739	0.00373	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP2E1—liver cancer	0.000737	0.00983	CbGpPWpGaD
Eprosartan—Vascular purpura—Doxorubicin—liver cancer	0.000737	0.00372	CcSEcCtD
Eprosartan—Eczema—Doxorubicin—liver cancer	0.000733	0.0037	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—CDH1—liver cancer	0.00073	0.00974	CbGpPWpGaD
Eprosartan—Cardiac failure—Epirubicin—liver cancer	0.00073	0.00368	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—TRIO—liver cancer	0.000717	0.00956	CbGpPWpGaD
Eprosartan—Hyponatraemia—Epirubicin—liver cancer	0.000715	0.00361	CcSEcCtD
Eprosartan—Osteoarthritis—Epirubicin—liver cancer	0.000712	0.0036	CcSEcCtD
Eprosartan—Hot flush—Doxorubicin—liver cancer	0.000704	0.00356	CcSEcCtD
Eprosartan—Migraine—Epirubicin—liver cancer	0.000701	0.00354	CcSEcCtD
Eprosartan—Menopausal symptoms—Doxorubicin—liver cancer	0.000698	0.00353	CcSEcCtD
Eprosartan—Hypersensitivity—Sorafenib—liver cancer	0.000698	0.00352	CcSEcCtD
Eprosartan—Face oedema—Epirubicin—liver cancer	0.000688	0.00347	CcSEcCtD
Eprosartan—Purpura—Doxorubicin—liver cancer	0.000684	0.00345	CcSEcCtD
Eprosartan—Asthenia—Sorafenib—liver cancer	0.00068	0.00343	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCR4—liver cancer	0.000679	0.00905	CbGpPWpGaD
Eprosartan—Cardiac failure—Doxorubicin—liver cancer	0.000675	0.00341	CcSEcCtD
Eprosartan—Pruritus—Sorafenib—liver cancer	0.00067	0.00338	CcSEcCtD
Eprosartan—Ataxia—Epirubicin—liver cancer	0.00067	0.00338	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—liver cancer	0.000669	0.00893	CbGpPWpGaD
Eprosartan—Blood creatinine increased—Epirubicin—liver cancer	0.000667	0.00337	CcSEcCtD
Eprosartan—Hyponatraemia—Doxorubicin—liver cancer	0.000662	0.00334	CcSEcCtD
Eprosartan—Osteoarthritis—Doxorubicin—liver cancer	0.000659	0.00333	CcSEcCtD
Eprosartan—Orthostatic hypotension—Epirubicin—liver cancer	0.00065	0.00328	CcSEcCtD
Eprosartan—Migraine—Doxorubicin—liver cancer	0.000649	0.00328	CcSEcCtD
Eprosartan—Hypokalaemia—Epirubicin—liver cancer	0.000648	0.00327	CcSEcCtD
Eprosartan—Diarrhoea—Sorafenib—liver cancer	0.000648	0.00327	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTA3—liver cancer	0.000642	0.00856	CbGpPWpGaD
Eprosartan—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000641	0.00324	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.000641	0.00855	CbGpPWpGaD
Eprosartan—Face oedema—Doxorubicin—liver cancer	0.000636	0.00321	CcSEcCtD
Eprosartan—Gastritis—Epirubicin—liver cancer	0.00063	0.00318	CcSEcCtD
Eprosartan—Muscular weakness—Epirubicin—liver cancer	0.000628	0.00317	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000628	0.00317	CcSEcCtD
Eprosartan—Dizziness—Sorafenib—liver cancer	0.000626	0.00316	CcSEcCtD
Eprosartan—Ataxia—Doxorubicin—liver cancer	0.00062	0.00313	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.00062	0.00826	CbGpPWpGaD
Eprosartan—Blood creatinine increased—Doxorubicin—liver cancer	0.000617	0.00312	CcSEcCtD
Eprosartan—Asthma—Epirubicin—liver cancer	0.000616	0.00311	CcSEcCtD
Eprosartan—Vomiting—Sorafenib—liver cancer	0.000602	0.00304	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—liver cancer	0.000602	0.00304	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—liver cancer	0.0006	0.00303	CcSEcCtD
Eprosartan—Angina pectoris—Epirubicin—liver cancer	0.0006	0.00303	CcSEcCtD
Eprosartan—Rash—Sorafenib—liver cancer	0.000597	0.00302	CcSEcCtD
Eprosartan—Dermatitis—Sorafenib—liver cancer	0.000597	0.00301	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000593	0.003	CcSEcCtD
Eprosartan—Headache—Sorafenib—liver cancer	0.000593	0.003	CcSEcCtD
Eprosartan—Bronchitis—Epirubicin—liver cancer	0.000592	0.00299	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTA4—liver cancer	0.000587	0.00783	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000584	0.00779	CbGpPWpGaD
Eprosartan—Gastritis—Doxorubicin—liver cancer	0.000583	0.00294	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—liver cancer	0.000581	0.00293	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000581	0.00293	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Epirubicin—liver cancer	0.000572	0.00289	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTA2—liver cancer	0.000572	0.00763	CbGpPWpGaD
Eprosartan—Asthma—Doxorubicin—liver cancer	0.00057	0.00288	CcSEcCtD
Eprosartan—Pollakiuria—Epirubicin—liver cancer	0.000569	0.00287	CcSEcCtD
Eprosartan—Nausea—Sorafenib—liver cancer	0.000563	0.00284	CcSEcCtD
Eprosartan—Hyperglycaemia—Epirubicin—liver cancer	0.000555	0.0028	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—liver cancer	0.000555	0.0028	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTA1—liver cancer	0.000552	0.00736	CbGpPWpGaD
Eprosartan—CYP2C9—Xenobiotics—CYP1A1—liver cancer	0.00055	0.00734	CbGpPWpGaD
Eprosartan—Bronchitis—Doxorubicin—liver cancer	0.000548	0.00277	CcSEcCtD
Eprosartan—Renal failure—Epirubicin—liver cancer	0.00054	0.00272	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—CTNNB1—liver cancer	0.000539	0.00719	CbGpPWpGaD
Eprosartan—Neuropathy peripheral—Epirubicin—liver cancer	0.000538	0.00272	CcSEcCtD
Eprosartan—Urinary tract infection—Epirubicin—liver cancer	0.000533	0.00269	CcSEcCtD
Eprosartan—Conjunctivitis—Epirubicin—liver cancer	0.000533	0.00269	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000531	0.00709	CbGpPWpGaD
Eprosartan—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000529	0.00267	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP1A1—liver cancer	0.000529	0.00706	CbGpPWpGaD
Eprosartan—Pollakiuria—Doxorubicin—liver cancer	0.000526	0.00266	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—liver cancer	0.000523	0.00264	CcSEcCtD
Eprosartan—Epistaxis—Epirubicin—liver cancer	0.000518	0.00261	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—liver cancer	0.000515	0.0026	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—liver cancer	0.000514	0.00259	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—liver cancer	0.000502	0.00253	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—liver cancer	0.000501	0.00669	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000501	0.00668	CbGpPWpGaD
Eprosartan—Renal failure—Doxorubicin—liver cancer	0.000499	0.00252	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—liver cancer	0.000498	0.00251	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—liver cancer	0.000494	0.00249	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—liver cancer	0.000494	0.00249	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—liver cancer	0.000494	0.00249	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK8—liver cancer	0.000489	0.00653	CbGpPWpGaD
Eprosartan—Pharyngitis—Epirubicin—liver cancer	0.000489	0.00247	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—NFE2L2—liver cancer	0.000486	0.00649	CbGpPWpGaD
Eprosartan—Oedema peripheral—Epirubicin—liver cancer	0.000485	0.00245	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—liver cancer	0.000484	0.00244	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—liver cancer	0.000479	0.00242	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—liver cancer	0.000476	0.00241	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—liver cancer	0.000475	0.0024	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000473	0.00631	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000472	0.0063	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000472	0.0063	CbGpPWpGaD
Eprosartan—Bradycardia—Doxorubicin—liver cancer	0.000464	0.00234	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GPX3—liver cancer	0.000464	0.00619	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFA—liver cancer	0.000464	0.00619	CbGpPWpGaD
Eprosartan—Tinnitus—Epirubicin—liver cancer	0.000459	0.00232	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SERPINA1—liver cancer	0.000457	0.0061	CbGpPWpGaD
Eprosartan—Rhinitis—Doxorubicin—liver cancer	0.000457	0.00231	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000455	0.00607	CbGpPWpGaD
Eprosartan—Pharyngitis—Doxorubicin—liver cancer	0.000452	0.00228	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—HPGDS—liver cancer	0.000451	0.00602	CbGpPWpGaD
Eprosartan—Oedema peripheral—Doxorubicin—liver cancer	0.000449	0.00227	CcSEcCtD
Eprosartan—Chills—Epirubicin—liver cancer	0.000442	0.00223	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—liver cancer	0.000439	0.00222	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—UGDH—liver cancer	0.00043	0.00574	CbGpPWpGaD
Eprosartan—Tinnitus—Doxorubicin—liver cancer	0.000425	0.00215	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—liver cancer	0.000423	0.00213	CcSEcCtD
Eprosartan—Tension—Epirubicin—liver cancer	0.000421	0.00213	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—liver cancer	0.000417	0.0021	CcSEcCtD
Eprosartan—Back pain—Epirubicin—liver cancer	0.000415	0.00209	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—liver cancer	0.000412	0.00208	CcSEcCtD
Eprosartan—Chills—Doxorubicin—liver cancer	0.000409	0.00207	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—liver cancer	0.000398	0.00201	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—PRKCE—liver cancer	0.000396	0.00528	CbGpPWpGaD
Eprosartan—Flatulence—Doxorubicin—liver cancer	0.000391	0.00197	CcSEcCtD
Eprosartan—Tension—Doxorubicin—liver cancer	0.000389	0.00197	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—liver cancer	0.000387	0.00516	CbGpPWpGaD
Eprosartan—Malaise—Epirubicin—liver cancer	0.000387	0.00195	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—liver cancer	0.000385	0.00195	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—liver cancer	0.000385	0.00195	CcSEcCtD
Eprosartan—Syncope—Epirubicin—liver cancer	0.000385	0.00194	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—liver cancer	0.000384	0.00194	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—liver cancer	0.000382	0.00193	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—liver cancer	0.000379	0.00191	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—liver cancer	0.000377	0.0019	CcSEcCtD
Eprosartan—Cough—Epirubicin—liver cancer	0.000374	0.00189	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—CASP3—liver cancer	0.000369	0.00492	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL2—liver cancer	0.000369	0.00492	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Doxorubicin—liver cancer	0.000368	0.00186	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—liver cancer	0.000365	0.00184	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—liver cancer	0.000365	0.00184	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—liver cancer	0.000365	0.00184	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—liver cancer	0.000364	0.00184	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—liver cancer	0.000361	0.00182	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—liver cancer	0.000358	0.00181	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—liver cancer	0.000357	0.0018	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—liver cancer	0.000357	0.0018	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—liver cancer	0.000356	0.0018	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.000354	0.00472	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—liver cancer	0.000353	0.00471	CbGpPWpGaD
Eprosartan—Palpitations—Doxorubicin—liver cancer	0.000351	0.00177	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—liver cancer	0.000349	0.00176	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CCR4—liver cancer	0.000347	0.00462	CbGpPWpGaD
Eprosartan—Cough—Doxorubicin—liver cancer	0.000346	0.00175	CcSEcCtD
Eprosartan—Shock—Epirubicin—liver cancer	0.000344	0.00174	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—liver cancer	0.000343	0.00173	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—liver cancer	0.000342	0.00173	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—liver cancer	0.000338	0.00171	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GGT1—liver cancer	0.000338	0.00451	CbGpPWpGaD
Eprosartan—Arthralgia—Doxorubicin—liver cancer	0.000338	0.00171	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—liver cancer	0.000338	0.00171	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—liver cancer	0.000338	0.00171	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—liver cancer	0.000337	0.0017	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—liver cancer	0.000334	0.00169	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—liver cancer	0.000334	0.00168	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—liver cancer	0.00033	0.00167	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000329	0.00439	CbGpPWpGaD
Eprosartan—Hypotension—Epirubicin—liver cancer	0.000327	0.00165	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GGT1—liver cancer	0.000326	0.00435	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000319	0.00161	CcSEcCtD
Eprosartan—Shock—Doxorubicin—liver cancer	0.000319	0.00161	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000318	0.00424	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Doxorubicin—liver cancer	0.000317	0.0016	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—liver cancer	0.000317	0.0016	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—liver cancer	0.000316	0.0016	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—liver cancer	0.000314	0.00159	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000314	0.00419	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—liver cancer	0.000313	0.00418	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Doxorubicin—liver cancer	0.000313	0.00158	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—liver cancer	0.000312	0.00158	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—liver cancer	0.000311	0.00157	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—liver cancer	0.000309	0.00156	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—liver cancer	0.000308	0.00156	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—liver cancer	0.000304	0.00154	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—liver cancer	0.000303	0.00153	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—liver cancer	0.000302	0.00152	CcSEcCtD
Eprosartan—Constipation—Epirubicin—liver cancer	0.000299	0.00151	CcSEcCtD
Eprosartan—Pain—Epirubicin—liver cancer	0.000299	0.00151	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000295	0.00149	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—liver cancer	0.000293	0.00391	CbGpPWpGaD
Eprosartan—Insomnia—Doxorubicin—liver cancer	0.000293	0.00148	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—liver cancer	0.000291	0.00147	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—HMOX1—liver cancer	0.000289	0.00386	CbGpPWpGaD
Eprosartan—Dyspnoea—Doxorubicin—liver cancer	0.000289	0.00146	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—liver cancer	0.000288	0.00146	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—liver cancer	0.000288	0.00384	CbGpPWpGaD
Eprosartan—Somnolence—Doxorubicin—liver cancer	0.000288	0.00145	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—liver cancer	0.000288	0.00384	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Epirubicin—liver cancer	0.000286	0.00145	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—liver cancer	0.000285	0.00144	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—liver cancer	0.000282	0.00142	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—liver cancer	0.000279	0.00141	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—liver cancer	0.000278	0.0014	CcSEcCtD
Eprosartan—Pain—Doxorubicin—liver cancer	0.000277	0.0014	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—liver cancer	0.000277	0.0014	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—liver cancer	0.000277	0.0014	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—liver cancer	0.000277	0.0014	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—F2—liver cancer	0.000275	0.00366	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000272	0.00363	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—F2—liver cancer	0.000271	0.00362	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTM1—liver cancer	0.000269	0.00359	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—HGF—liver cancer	0.000269	0.00359	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—liver cancer	0.000269	0.00358	CbGpPWpGaD
Eprosartan—Feeling abnormal—Doxorubicin—liver cancer	0.000267	0.00135	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—liver cancer	0.000265	0.00134	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000264	0.00353	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CHN2—liver cancer	0.000264	0.00352	CbGpPWpGaD
Eprosartan—Hypersensitivity—Epirubicin—liver cancer	0.000258	0.0013	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000258	0.00344	CbGpPWpGaD
Eprosartan—Urticaria—Doxorubicin—liver cancer	0.000257	0.0013	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—liver cancer	0.000256	0.00129	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—liver cancer	0.000256	0.00129	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—NR1H4—liver cancer	0.000251	0.00335	CbGpPWpGaD
Eprosartan—Asthenia—Epirubicin—liver cancer	0.000251	0.00127	CcSEcCtD
Eprosartan—Pruritus—Epirubicin—liver cancer	0.000248	0.00125	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA3—liver cancer	0.000247	0.0033	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.000246	0.00328	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTA3—liver cancer	0.000244	0.00325	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000242	0.00322	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IFT88—liver cancer	0.000241	0.00322	CbGpPWpGaD
Eprosartan—Diarrhoea—Epirubicin—liver cancer	0.00024	0.00121	CcSEcCtD
Eprosartan—Hypersensitivity—Doxorubicin—liver cancer	0.000239	0.0012	CcSEcCtD
Eprosartan—Asthenia—Doxorubicin—liver cancer	0.000232	0.00117	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—liver cancer	0.000231	0.00117	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000231	0.00307	CbGpPWpGaD
Eprosartan—Pruritus—Doxorubicin—liver cancer	0.000229	0.00116	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000229	0.00305	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.000226	0.00302	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000226	0.00301	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.000223	0.00297	CbGpPWpGaD
Eprosartan—Vomiting—Epirubicin—liver cancer	0.000223	0.00112	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—liver cancer	0.000222	0.00112	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000221	0.00295	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000221	0.00295	CbGpPWpGaD
Eprosartan—Rash—Epirubicin—liver cancer	0.000221	0.00111	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—liver cancer	0.000221	0.00111	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.00022	0.00294	CbGpPWpGaD
Eprosartan—Headache—Epirubicin—liver cancer	0.000219	0.00111	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—liver cancer	0.000214	0.00108	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.000213	0.00284	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—NAT2—liver cancer	0.00021	0.0028	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000209	0.00279	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—liver cancer	0.000208	0.00105	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.000207	0.00276	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—liver cancer	0.000206	0.00104	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—TRIO—liver cancer	0.000204	0.00273	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—liver cancer	0.000204	0.00103	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—liver cancer	0.000204	0.00103	CcSEcCtD
Eprosartan—Headache—Doxorubicin—liver cancer	0.000203	0.00102	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCR4—liver cancer	0.000196	0.00261	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—liver cancer	0.000192	0.000971	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—TRIO—liver cancer	0.000186	0.00248	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000185	0.00247	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000185	0.00246	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000182	0.00243	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCR4—liver cancer	0.000178	0.00237	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	0.000176	0.00235	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—HPGDS—liver cancer	0.000168	0.00224	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000155	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SHC3—liver cancer	0.000148	0.00197	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—F2—liver cancer	0.000139	0.00185	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2E1—liver cancer	0.000137	0.00183	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	0.000135	0.0018	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GGT1—liver cancer	0.000126	0.00168	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—liver cancer	0.000123	0.00164	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.00012	0.00159	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FST—liver cancer	0.000115	0.00153	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—liver cancer	0.000113	0.00151	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PRKCE—liver cancer	0.000113	0.0015	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	0.000111	0.00149	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.00011	0.00147	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—liver cancer	0.00011	0.00146	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TRIO—liver cancer	0.00011	0.00146	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000107	0.00142	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR4—liver cancer	0.000105	0.0014	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—liver cancer	0.000104	0.00138	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PRKCE—liver cancer	0.000102	0.00137	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	0.000102	0.00137	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000102	0.00136	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.0001	0.00134	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CSF2—liver cancer	9.98e-05	0.00133	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP1A1—liver cancer	9.84e-05	0.00131	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	9.73e-05	0.0013	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	9.71e-05	0.00129	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	9.65e-05	0.00129	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—HMOX1—liver cancer	9.26e-05	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CSF2—liver cancer	9.06e-05	0.00121	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADAM17—liver cancer	8.31e-05	0.00111	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—F2—liver cancer	7.83e-05	0.00104	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSMA4—liver cancer	7.81e-05	0.00104	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSMD10—liver cancer	7.81e-05	0.00104	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—liver cancer	7.49e-05	0.001	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	7.48e-05	0.000998	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	7.38e-05	0.000985	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGDH—liver cancer	7.36e-05	0.000982	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—F2—liver cancer	7.11e-05	0.000948	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EPT1—liver cancer	6.92e-05	0.000923	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—liver cancer	6.81e-05	0.000908	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—liver cancer	6.59e-05	0.000879	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TAT—liver cancer	6.56e-05	0.000875	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	6.45e-05	0.000861	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRKCE—liver cancer	6.05e-05	0.000807	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—liver cancer	5.98e-05	0.000798	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—liver cancer	5.74e-05	0.000766	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF2—liver cancer	5.73e-05	0.000765	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	5.56e-05	0.000742	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CSF2—liver cancer	5.35e-05	0.000714	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—liver cancer	5.34e-05	0.000712	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—H2AFX—liver cancer	5.28e-05	0.000704	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—liver cancer	5.27e-05	0.000703	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—liver cancer	5.21e-05	0.000696	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	5.03e-05	0.000671	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.83e-05	0.000644	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—liver cancer	4.79e-05	0.000639	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—liver cancer	4.77e-05	0.000636	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CPT1B—liver cancer	4.46e-05	0.000595	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GLUL—liver cancer	4.46e-05	0.000595	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—liver cancer	4.36e-05	0.000582	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK14—liver cancer	4.34e-05	0.000578	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NR1H4—liver cancer	4.3e-05	0.000573	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—liver cancer	4.25e-05	0.000567	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA3—liver cancer	4.23e-05	0.000564	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—F2—liver cancer	4.2e-05	0.00056	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—liver cancer	4.02e-05	0.000536	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—liver cancer	4.02e-05	0.000536	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA4—liver cancer	3.87e-05	0.000516	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.78e-05	0.000504	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—liver cancer	3.78e-05	0.000504	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA2—liver cancer	3.77e-05	0.000503	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA1—liver cancer	3.64e-05	0.000485	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT2—liver cancer	3.59e-05	0.000479	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—liver cancer	3.53e-05	0.000471	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—liver cancer	3.5e-05	0.000467	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—liver cancer	3.5e-05	0.000466	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—liver cancer	3.46e-05	0.000461	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.46e-05	0.000461	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDOB—liver cancer	3.45e-05	0.00046	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CRABP1—liver cancer	3.29e-05	0.000438	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—liver cancer	3.18e-05	0.000424	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—liver cancer	3.16e-05	0.000421	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTOR—liver cancer	3.08e-05	0.000411	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—liver cancer	3.08e-05	0.000411	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.96e-05	0.000395	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—liver cancer	2.94e-05	0.000392	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1B—liver cancer	2.89e-05	0.000386	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGDS—liver cancer	2.87e-05	0.000383	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—liver cancer	2.86e-05	0.000381	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.86e-05	0.000381	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—liver cancer	2.83e-05	0.000378	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—liver cancer	2.83e-05	0.000377	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—liver cancer	2.81e-05	0.000375	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—liver cancer	2.76e-05	0.000368	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—liver cancer	2.75e-05	0.000367	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNB1—liver cancer	2.73e-05	0.000364	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—liver cancer	2.68e-05	0.000357	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—liver cancer	2.67e-05	0.000356	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK8—liver cancer	2.6e-05	0.000347	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.6e-05	0.000347	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—liver cancer	2.6e-05	0.000346	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.57e-05	0.000343	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSMA4—liver cancer	2.56e-05	0.000342	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSMD10—liver cancer	2.56e-05	0.000342	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GOT2—liver cancer	2.49e-05	0.000332	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—liver cancer	2.4e-05	0.000321	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—liver cancer	2.38e-05	0.000318	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2E1—liver cancer	2.34e-05	0.000312	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.27e-05	0.000302	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—liver cancer	2.21e-05	0.000295	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—liver cancer	2.21e-05	0.000294	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYCS—liver cancer	2.19e-05	0.000292	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GGT1—liver cancer	2.15e-05	0.000287	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GOT1—liver cancer	2.15e-05	0.000287	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—liver cancer	2.04e-05	0.000273	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—liver cancer	1.93e-05	0.000258	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMOX1—liver cancer	1.91e-05	0.000254	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—liver cancer	1.88e-05	0.00025	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—liver cancer	1.82e-05	0.000242	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—liver cancer	1.78e-05	0.000237	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—liver cancer	1.74e-05	0.000232	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—liver cancer	1.68e-05	0.000224	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—liver cancer	1.66e-05	0.000222	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—liver cancer	1.57e-05	0.000209	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARA—liver cancer	1.54e-05	0.000205	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—liver cancer	1.53e-05	0.000205	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.38e-05	0.000184	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—liver cancer	1.32e-05	0.000176	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—liver cancer	1.27e-05	0.00017	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—liver cancer	1.16e-05	0.000155	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—liver cancer	1.14e-05	0.000153	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—liver cancer	1.01e-05	0.000135	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—liver cancer	6.16e-06	8.21e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—liver cancer	5.03e-06	6.71e-05	CbGpPWpGaD
